Head to Head Contrast: Climb Bio (CLYM) & Its Competitors

Climb Bio (NASDAQ:CLYM) is one of 1,060 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Climb Bio to similar businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Climb Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Climb Bio and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7772	21188	48893	1232	2.55

Climb Bio currently has a consensus target price of $10.00, indicating a potential upside of 412.82%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.75%. Given Climb Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Climb Bio is more favorable than its rivals.

Risk & Volatility

Climb Bio has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s rivals have a beta of 3.71, meaning that their average share price is 271% more volatile than the S&P 500.

Valuation & Earnings

This table compares Climb Bio and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.92
Climb Bio Competitors	$9.58 billion	$147.39 million	-5.43

Climb Bio’s rivals have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.2% of Climb Bio shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Climb Bio beats its rivals on 7 of the 13 factors compared.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.